IP Library Granted Patent US 11,285,280
Granted Patent B2
US 11,285,280 · App. 16/825,840 · Granted Mar 29, 2022

Intelligent gas source management

Inventors: Jaron M. Acker (Madison, WI); Craig R. Tolmie (Stoughton, WI); Robin Roehl (Janesville, WI); Jeffrey Schmidt (Fitchburg, WI); Jeff Milsap (Cambridge, WI)
Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
A61M16/0051A61M16/024A61M16/1005A61M16/12A61M16/122A61M16/125A61M16/201A61M16/202A61M16/204B63C11/02G01F22/02A61M16/085A61M16/208A61M2016/0027A61M2016/0039A61M2016/102A61M2202/0275A61M2205/14A61M2205/16A61M2205/17A61M2205/3331A61M2205/3334A61M2205/3368A61M2205/3379A61M2205/50A61M2205/502A61M2205/52A61M2205/60A61M2205/6018A61M2205/6072A61M2205/8206F17C2250/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,285,280
App. No.
16/825,840
Granted
Mar 29, 2022
Kind
B2
Abstract

Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system. The therapeutic gas delivery system controller of the system includes a processor that executes an algorithm to calculate the run-time-to-empty from the data received from the gas pressure sensor, temperature sensor, flow controller and flow sensor, and directs the result to the display.

Claims (17)

1. A therapeutic gas source comprising:

a compressed gas cylinder of therapeutic gas operable to be detected by a therapeutic gas source detector as being properly received by a gas source coupling in a therapeutic gas delivery system; and

at least one gas source identifier containing gas source identifier information, the at least one gas source identifier attached to the compressed gas cylinder and operable to be read by a gas source identifier reader operatively associated with the therapeutic gas delivery system when the compressed gas cylinder is properly received by the gas source coupling in the therapeutic gas delivery system to communicate the gas source identifier information to a therapeutic gas delivery system controller, wherein the gas source identifier is selected from the group consisting of RFID, a QR code, a bar code, or combinations thereof.

2. The therapeutic gas source of claim 1 , wherein the compressed gas cylinder comprises an initial gas pressure of about 2000 psi to about 5000 psi.

3. The therapeutic gas source of claim 1 , wherein the gas source identifier information includes therapeutic gas concentration, wherein the therapeutic gas concentration is about 2000 ppm to about 10000 ppm.

4. The therapeutic gas source of claim 3 , wherein the therapeutic gas concentration is about 4880 ppm.

5. The therapeutic gas source of claim 1 , wherein the gas source identifier information comprises gas source volume supplied by the therapeutic gas source, and wherein the gas source volume is a wetted volume of the gas source.

6. The therapeutic gas source of claim 1 , wherein the therapeutic gas is nitric oxide.

7. The therapeutic gas source of claim 1 , wherein the therapeutic gas source further comprises a gas source valve operable to be received by the gas source coupling.

8. The therapeutic gas source of claim 1 , wherein the gas source identifier information includes therapeutic gas identity.

9. The therapeutic gas source of claim 1 , wherein the gas source identifier information includes therapeutic gas expiration date.

10. A therapeutic gas source comprising:

a compressed gas cylinder of therapeutic gas comprising an initial gas pressure of 2000 psi to 5000 psi and a concentration of 2000 ppm to 10000 ppm, wherein the compressed gas cylinder weighs less than ⅓ the weight of a standard sized gas cylinder; and

at least one gas source identifier containing gas source identifier information, the at least one gas source identifier attached to the compressed gas cylinder and operable to be read by a gas source identifier reader to communicate the gas source identifier information to a therapeutic gas delivery system controller, wherein the gas source identifier is selected from the group consisting of RFID, a QR code, a bar code, or combinations thereof.

11. The therapeutic gas source of claim 10 , wherein the compressed gas cylinder weighs less than 10 lbs.

12. The therapeutic gas source of claim 11 , wherein the compressed gas cylinder weighs 1.4 lbs.

13. The therapeutic gas source of claim 10 , wherein the therapeutic gas is nitric oxide.

Assignments (13)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED COMPANY
Reel/Frame 075393/0361 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 73375 FRAME 395. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0263 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 72331 FRAME 1. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075021/0204 →
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
CHANGE OF NAME Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 056476/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 056433/0640 →